PROCEPT BioRobotics (PRCT) vs DENTSPLY SIRONA (XRAY)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
PROCEPT BioRobotics (PRCT) has outperformed DENTSPLY SIRONA (XRAY) over the past year, losing 17.3% versus a loss of 21.6%. Over five years, PRCT leads with a -30.6% price change compared with -83.4% for XRAY. DENTSPLY SIRONA is the larger company by market cap ($1.65 billion vs $1.42 billion), about 1.2 times the size, while PROCEPT BioRobotics is growing revenue faster (+37.2% vs -3.0%).
DENTSPLY SIRONA pays a dividend yielding 1.93%, while PROCEPT BioRobotics does not currently pay one. DENTSPLY SIRONA converts more of its revenue into profit, with a net margin of -16.3% versus -31.0%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | PRCT | XRAY |
|---|---|---|
| Share price | $24.70 | $8.29 |
| Market cap | $1.42B | $1.65B |
| 1-day change | -4.08% | -2.36% |
| YTD return | -21.49% | -27.47% |
| 1-year return | -17.28% | -21.64% |
| 5-year return | -30.64% | -83.35% |
| Forward P/E | — | 6.78 |
| EPS (TTM) | $-2.02 | $-0.61 |
| Dividend yield | 0.00% | 1.93% |
| Annual dividend | $0.00 | $0.16 |
| Revenue (latest FY) | $308.05M | $3.68B |
| Revenue growth (YoY) | +37.22% | -2.98% |
| Net income (latest FY) | $-95.57M | $-598.00M |
| Gross margin | 63.70% | 50.00% |
| Operating margin | -33.71% | -11.47% |
| Net margin | -31.02% | -16.25% |
| 52-week high | $38.11 | $14.76 |
| 52-week low | $16.67 | $8.14 |
| Distance from 52-week high | -35.19% | -43.83% |
| Analyst consensus | hold | hold |
| Avg. price target upside | -7.89% | +29.92% |
| Average volume | 1.31M | 4.81M |
| Shares outstanding | 57.54M | 199.35M |
| Employees | 888 | 14,000 |
| Sector | Health Care | Health Care |
| Industry | Medical/Dental Instruments | Medical/Dental Instruments |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- DENTSPLY SIRONA offers a meaningfully higher dividend yield (1.93% vs 0.00%).
- DENTSPLY SIRONA is more profitable, keeping -16.3 cents of every revenue dollar as net income versus -31.0 cents for PROCEPT BioRobotics.
- PROCEPT BioRobotics grew revenue faster in its latest fiscal year (+37.22% vs -2.98%).
About PROCEPT BioRobotics
PRCT stock →PROCEPT BioRobotics Corporation, a surgical robotics company, develops transformative solutions in urology in the United States and internationally. It develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally invasive urologic surgery focusing on treating benign prostatic hyperplasia.
Health Care · Medical/Dental Instruments · 888 employees
About DENTSPLY SIRONA
XRAY stock →DENTSPLY SIRONA Inc. develops, manufactures, and markets dental equipment supported by cloud-enabled solutions, dental products, and healthcare consumable products in urology and enterology worldwide.
Health Care · Medical/Dental Instruments · 14,000 employees
PRCT vs XRAY FAQ
Which is bigger, PROCEPT BioRobotics or DENTSPLY SIRONA?
DENTSPLY SIRONA (XRAY) is larger, with a market capitalization of $1.65B compared with $1.42B for PROCEPT BioRobotics (PRCT).
Which stock has performed better over the past year, PRCT or XRAY?
PRCT returned -17.28% over the past 12 months, compared with -21.64% for XRAY (price return, excluding dividends). Past performance does not predict future results.
Which pays a higher dividend, PROCEPT BioRobotics or DENTSPLY SIRONA?
DENTSPLY SIRONA pays a dividend yielding 1.93%, while PROCEPT BioRobotics does not currently pay a regular dividend.
Are PROCEPT BioRobotics and DENTSPLY SIRONA in the same industry?
Yes. Both are classified in the Medical/Dental Instruments industry within the Health Care sector.